Immune Cell Function Assay Comm Bc Ma Dsnp G2098
This policy defines coverage determinations for immune cell function assays used to measure peripheral blood lymphocyte/T-cell function (eg, ATP levels, CD154 assays) for diagnosis or management, including proprietary tests (ImmuKnow, Pleximmune, iQue) and applicable CPT/HCPCS codes. It notes relation to Medicare/Medicaid and FDA status.
No material clinical or coverage changes were made in this update.
Coverage Summary
This policy defines coverage determinations for immune cell function assays used to measure peripheral blood lymphocyte/T-cell function (eg, ATP levels, CD154 assays) for diagnosis or management, including proprietary tests ImmuKnow, Pleximmune, and iQue, and references applicable CPT/HCPCS procedure codes. Primary coverage stance: these assays are not covered (do not meet coverage criteria) due to insufficient published evidence of required clinical benefit.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.